SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 7, 2026

CLRB

Cellectar Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago
Insider cluster: 2 insiders, $50K total
Actionable Insight ▼ Bearish

The insider buying at a premium provides a slight positive signal, but the overwhelming dilution from the offering suggests further downside. The stock is likely to remain under pressure.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
CLRB ▼ -19.39% at T+60d
SHORT call ✓ call won +19.39% · α vs SPY +23.23% · entry $3.30 → $2.66
Entry = T+0 close
May 6, 2026
via day close
T+1d
-6.06%
call +6.06% · α +6.89%
$3.10
settled 6mo ago
T+5d
-10.91%
call +10.91% · α +12.41%
$2.94
settled 6mo ago
T+20d
-21.21%
call +21.21% · α +24.35%
$2.60
settled 5mo ago
T+60d
-19.39%
call +19.39% · α +23.23%
$2.66
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

CLRB's CEO and COO purchased $50K in shares at $2.88, a premium to the heavily dilutive $34.95M offering priced at $2.65. While insider buying at a premium signals some confidence, the massive dilution from 300% warrant coverage and the company's cash crisis dominate the outlook.

Key Financial Metrics

Direction
buying
Total Value
$50.0K
Insiders
2

Key Facts

  • CEO James Caruso and COO Jarrod Longcor each purchased $25K in shares at $2.88 on May 7, 2026
  • Total insider purchases of $50K represent ~0.38% of the $13M market cap
  • Purchases occurred immediately after the company announced a $34.95M offering with 300% warrant coverage
  • The offering price of $2.65 was below the insider purchase price of $2.88, a premium of 8.7%
  • Proceeds from the offering are insufficient to fully fund regulatory strategy, per the company

Financial Impact

Insider purchases of $50K are modest relative to the $34.95M offering, which will massively dilute existing shareholders

dilutioncashmarket cap

Risk Factors

  • Severe dilution from the 300% warrant coverage could suppress share price for an extended period
  • Cash burn and going-concern risk highlighted by the insufficient capital raise

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CLRB-1778544467689
17 reports for CLRB
Performance horizon
57% Hit rate @ T+60 4 of 7 directional calls Went positive at some point 5 of 8 best @ T+60▲ +27.20%May 6, 2026
Filters
Rows
Reports for CLRB — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
Press Release
BULLISH ★ 6/10
$1.19awaiting T+60—$1.22 (+2.52%)
Aug 13, 2026
10w ago
8-K
NEUTRAL ★ 4/10
$2.48awaiting T+60—$1.22 (−50.81%)
Aug 13, 2026
10w ago
Press Release
NEUTRAL ★ 4/10
$2.48awaiting T+60—$1.22 (−50.81%)
Jun 1, 2026
21w ago
Press Release
BULLISH ★ 7/10
$2.97 $2.54▼ −14.48%▼ −15.71%$1.22 (−58.92%)
May 29, 2026
21w ago
S-1/A
BEARISH ★ 6/10
$3.14 $2.52▲ +19.75%▲ +20.93%$1.22 (+61.15%)
May 28, 2026
21w ago
DEFA14A
NEUTRAL ★ 4/10
$3.14 $2.52▼ −19.75%▼ −20.93%$1.22 (−61.15%)
May 19, 2026
22w ago
S-1
BEARISH ★ 6/10
$3.17 $2.60▲ +17.98%▲ +22.98%$1.22 (+61.51%)
May 14, 2026
23w ago
8-K
MIXED ★ 7/10
$3.20 $2.60▼ −18.75%▼ −22.34%$1.22 (−61.87%)
May 14, 2026
23w ago
Press Release
BULLISH ★ 6/10
$3.20 $2.60▼ −18.75%▼ −22.34%$1.22 (−61.87%)
May 11, 2026
24w ago
Press Release
NEUTRAL ★ 1/10
$3.06 $2.52▼ −17.65%▼ −22.04%$1.22 (−60.13%)
Showing 10 of 17

US Market Status

Market Closed — Opens in 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026